Unlike estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 positive breast cancers, TNBCs cannot be treated with endocrine therapies or HER2-targeted agents (Trastuzumab, Pertuzumab), and chemotherapies are standard of care. The gene discussed is ERBB2; the disease is breast cancer.